#USA #Philadelphia #Pet Health #Vetigenics #CANIBODY

Vetigenics Secures $6 Million Seed Financing: A New Era for Pet Health

Vetigenics, a pioneering clinical-stage biotechnology firm focused on advancing antibody therapies for pets, has made headlines recently by closing a significant $6 million seed funding round. This investment marks a pivotal moment not only for the company but also for the realm of veterinary biotechnology, as it brings strong prospects for clinically impactful therapies aimed at addressing conditions like autoimmune diseases, obesity, and allergies in pets.

Major Achievements and Future Plans

The newly acquired funding will primarily drive Vetigenics' multiple clinical-stage programs into pivotal trials while also boosting preclinical candidates and scaling up operations and manufacturing capabilities. Adriann Sax, the President and CEO and co-founder of Vetigenics, elaborated on the significance of the funding, stating, "The funding underscores the confidence our investor partners have in our ability to achieve significant progress in a capital-efficient manner."

Significant Clinical Milestones

Vetigenics has also made strides in ongoing clinical trials, especially those targeting canine cancer treatment. Two notable trials have reached critical milestones:

• - VGS-001 (anti-cCTLA4): This antibody therapy was utilized in conjunction with palliative radiation to treat oral melanoma in dogs. Following the completion of the trial, promising results are slated for publication in 2025.
• - VGS-002 (anti-cPD1): Focused on dogs suffering from urothelial carcinoma, this monotherapy study is nearing its conclusion with anticipated positive results later this year.

Nicola Mason, a co-founder of Vetigenics, expressed excitement over these trials, stating, "It is very exciting to see Vetigenics' checkpoint inhibitors safely addressing significant unmet needs in common veterinary cancers."

Innovative Approaches to Common Pet Health Issues

Vetigenics isn’t just resting on its laurels with cancer treatments. The company is proactive in advancing therapeutic solutions for critical conditions affecting pets. The promising VGS-003 (anti-cCD19 mAb) for autoimmune disease treatment is currently being evaluated in live animal models and is set to enter clinical trials by the end of 2025.

Adriann Sax pointed out the advanced capabilities of Vetigenics' CANIBODY™ library, which enables the isolation of antibodies targeting some of the most challenging health issues in pets. Don Siegel, a co-founder and researcher at Vetigenics, added, "Our unique construction allows us to generate novel antibodies across various therapeutic areas and species."

Strengthened Leadership and Vision

In a bid to bolster its governance and strategic direction, Vetigenics has established a new board of directors featuring prominent leaders in the veterinary and biotechnology sectors. The board includes experts such as:

• - Chand Khanna, DVM, PhD: A preeminent figure in comparative oncology and translational medicine.
• - Stephen Lesser, JD, MBA: A strategic advisor with extensive experience in biotechnology and life sciences.
• - Caleb Frankel, VMD: A tech innovator known for pioneering electronic medical records in the veterinary industry.

With an enriched leadership team and a clear vision, Vetigenics is primed to make significant progress in 2025. The company's unwavering commitment to providing cutting-edge solutions aims to significantly enhance pets' health and well-being.

The Road Ahead

As Vetigenics continues to innovate and expand, the firm emphasizes its dedication to leveraging advanced science and collaborative efforts with industry partners and supporters. The company’s strategic approach not only underscores its growth potential but also illustrates its commitment to improving the lives of pets.

For more information about Vetigenics and its exciting projects in pet biotechnology, visit www.vetigenics.com and follow the company on LinkedIn.